Browse the evidence

Higher-quality protein sources (e.g., whey, milk) produce a significantly greater acute muscle protein synthesis (MPS) response than lower-quality sources (e.g., soy, wheat, casein) when matched for dose, both at rest and following resistance exercise.

If you are trying to maximize muscle growth, prioritize high-quality protein sources like whey, milk, eggs, or meat over lower-quality plant proteins (like wheat or soy) when possible. This is especially relevant for older adults who may experience 'anabolic resistance.' However, this is a small effect; hitting your total daily protein target is still the most important factor.

GLP-1 receptor agonists (e.g., liraglutide) produce significant weight loss (mean 8.4 kg over 56 weeks) by slowing gastric emptying and activating central satiety pathways, with 33.1% of patients achieving >10% body weight loss.

If you have obesity (BMI > 30, or > 27 with health issues), ask your doctor about GLP-1 agonists like liraglutide. This medication, taken daily, has been shown in clinical trials to help patients lose an average of 8.4 kg over a year, with many losing over 10% of their body weight. It works by slowing digestion and signaling fullness to your brain.

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) promote weight loss in obese individuals with type 2 diabetes, whereas sulfonylureas, thiazolidinediones, and insulin typically cause weight gain.

If you have type 2 diabetes and are obese, ask your doctor about SGLT2 inhibitors (like Jardiance/Farxiga) or GLP-1 agonists (like Ozempic/Victoza). These drugs lower blood sugar and typically help you lose 2-3 kg, whereas older drugs like insulin or sulfonylureas often make you gain weight. Combining these with metformin can enhance weight loss.

Dairy-based proteins, particularly whey, improve insulin sensitivity and muscle protein synthesis more effectively than other protein sources due to their insulinotropic properties and leucine content.

Incorporate 2-4 servings of dairy or 20-84g of whey protein daily. Whey is particularly effective because it stimulates insulin release without spiking blood sugar, helping to manage glucose and build muscle. Yogurt with probiotics is also beneficial for gut health and insulin sensitivity.

GLP-1 receptor agonists (semaglutide 2.4 mg/week and liraglutide 3 mg/day) produce significant weight loss in adults with obesity or overweight with comorbidities by delaying gastric emptying and increasing satiety, with semaglutide demonstrating superior efficacy compared to liraglutide.

If you have obesity or overweight with a related health condition, ask your doctor about GLP-1 agonists like semaglutide. They are taken as a once-weekly injection and work by making you feel full and slowing digestion. They are most effective when combined with a reduced-calorie diet and increased physical activity.

Intentional weight loss in older adults using anti-obesity medicines (AOMs) improves cardiometabolic outcomes and preserves skeletal muscle strength and bone mineral density, countering the risks of sarcopenia and functional decline.

If you are over 60 and have obesity, intentional weight loss using FDA-approved medications (like semaglutide or tirzepatide) combined with resistance training is safe and effective. It improves heart and metabolic health without necessarily causing frailty, provided you work with a clinician to manage side effects and maintain muscle mass.

Post-ACL reconstruction rehabilitation using Blood Flow Restriction (BFR) with low-load resistance training (30% 1RM) produces significantly greater gains in quadriceps and hamstring muscle strength and knee physical function compared to high-load resistance training (70% 1RM) without occlusion.

If you are in early rehab after ACL surgery, ask your physical therapist about Blood Flow Restriction (BFR) training. It allows you to use light weights (30% of your max) while still getting strong muscle gains, which is safer for your graft than heavy lifting. This method also helps reduce pain and improves knee function faster than standard heavy lifting in the first 3 months.

GLP-1 receptor agonists (GLP1RAs) produce significant weight loss and glycemic control in type 2 diabetes and obesity, with efficacy varying by specific agent, dose, and formulation.

If you have obesity or type 2 diabetes, GLP-1 drugs like semaglutide can help you lose significant weight and control blood sugar. You take it once a week. Side effects like nausea are common at first but usually go away. It works best when combined with healthy eating and exercise.

Triple agonist retatrutide (GLP-1/GIP/glucagon) produces superior weight loss (up to 24.2% at 12mg) compared to dual agonists and GLP-1 monotherapy, driven by synergistic activation of all three receptors.

Retatrutide, a once-weekly injection targeting three gut hormones, has shown unprecedented weight loss (up to 24%) in clinical trials for obesity. While effective, it carries a risk of gastrointestinal side effects like nausea, which are usually manageable by starting at a low dose and increasing slowly. It represents a significant advancement over older GLP-1 drugs.

Ingestion of 20–30 g of leucine-rich protein stimulates skeletal muscle protein synthesis and activates the mTORC1 pathway within 2 hours, an effect potentiated by prior resistance exercise.

To maximize muscle growth, consume 20–30 grams of high-quality protein (like meat, eggs, or dairy) per meal. This amount is sufficient to trigger your muscles' growth machinery (mTORC1). Doing this after resistance exercise helps, but you don't need massive amounts of extra protein beyond this threshold for each meal.

High-protein diets (above 25-30% energy) promote satiety and reduce fat mass without affecting lean mass, primarily through hormonal signaling (low ghrelin, high leptin) and reduced reward sensitivity.

To lose fat while keeping muscle, aim for a diet where 25-30% or more of your calories come from protein. This helps you feel full, reduces hunger hormones, and lowers your sensitivity to food rewards, making it easier to stick to a calorie deficit.

GLP-1 receptor agonists (including semaglutide, liraglutide, dulaglutide, and tirzepatide) significantly reduce hepatic lipid content and improve liver histology (steatosis, inflammation, and fibrosis) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), primarily through weight loss and direct metabolic modulation.

If you have fatty liver disease (MASLD) and struggle with weight or blood sugar, GLP-1 medications like semaglutide or tirzepatide are highly effective treatments. They don't just help you lose weight; they directly reduce fat in the liver and can reverse inflammation and early scarring. While they are injections and may cause temporary stomach upset, the clinical data shows they significantly improve liver health outcomes compared to placebo.

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant weight loss (6–30%+ TBWL) and improve fertility outcomes (spontaneous conception, IVF pregnancy rates) in women with obesity and PCOS when used in the preconception period.

If you have obesity and are trying to conceive, GLP-1 medications (like Wegovy or Zepbound) are highly effective for weight loss and improving fertility, especially if you have PCOS. You must stop taking them 2 months before you try to conceive to ensure the drug is out of your system. Work with your doctor to manage side effects and costs.

In obese patients with type 2 diabetes, GLP-1 receptor agonists significantly reduce the risk of major adverse cardiovascular events (MACE) compared to placebo, whereas SGLT-2 inhibitors show a non-significant trend.

If you have type 2 diabetes and are obese, GLP-1 receptor agonists (like liraglutide, semaglutide, or dulaglutide) have been proven to significantly lower your risk of major heart events compared to a placebo. SGLT-2 inhibitors also help but did not reach statistical significance in this specific obese subgroup analysis. Discuss GLP-1 RAs with your doctor as a first-line treatment for cardiovascular protection.

Once-daily oral semaglutide (3–14 mg) significantly reduces HbA1c (mean -1.16%-points) and body weight (mean -5.84 kg) in adults with type 2 diabetes over 34–44 weeks, with 47.5% achieving HbA1c < 7.0% and 35.5% achieving composite targets (HbA1c reduction ≥ 1.0%-points plus body weight reduction ≥ 5%).

If you have Type 2 Diabetes and are struggling with blood sugar and weight, oral semaglutide is a proven, once-daily option that can significantly lower your HbA1c and help you lose weight. Most people find it easy to take, and while stomach issues can happen, they are usually mild. It is particularly useful if you want to avoid injections.

Older adults require higher per-meal protein doses (0.40 g/kg) compared to younger adults (0.24 g/kg) to achieve maximal muscle protein synthesis due to anabolic resistance.

If you are over 60, you likely need more protein per meal than you think to build or keep muscle. Aim for about 0.4 grams of high-quality protein per kilogram of your body weight at each main meal (breakfast, lunch, dinner). This is roughly double the amount needed by a 20-year-old to trigger the same muscle-building response. Combine this with resistance exercise for best results.

Once-weekly subcutaneous semaglutide 2.4 mg injection is a cost-effective weight management therapy in the UK compared to diet and exercise alone, yielding an ICER of £14,827/QALY gained.

For patients in the UK with obesity and comorbidities, once-weekly semaglutide 2.4 mg combined with diet and exercise is a cost-effective treatment option approved by NICE. It offers significant health benefits over diet and exercise alone, with a stopping rule to ensure efficacy (5% weight loss at 6 months).

Supplementation with 15g of specific collagen peptides immediately following high-load resistance exercise significantly upregulates gene expression in the PI3K-Akt and MAPK anabolic signaling pathways in human skeletal muscle compared to placebo.

If you perform high-load resistance training, consuming 15g of specific collagen peptides immediately afterward may enhance the activation of key muscle-building signaling pathways (PI3K-Akt and MAPK) in your muscles compared to not taking them. This suggests collagen peptides can play a role in muscle adaptation when paired with exercise, even if they are not a complete protein source like whey.

Semaglutide 2.4 mg is the most cost-effective weight-management pharmacotherapy in Canada compared to standard of care (diet and exercise) and other approved drugs, primarily due to its superior ability to delay or prevent type 2 diabetes, sleep apnea, and cardiovascular events.

For adults in Canada with obesity (BMI ≥30 or ≥27 with comorbidities), Semaglutide 2.4 mg is currently the most cost-effective pharmacological treatment compared to diet/exercise alone or other drugs like Orlistat. It works by acting as a GLP-1 receptor agonist to promote weight loss and improve metabolic health. While it requires weekly injections and has a higher upfront cost, it significantly reduces the long-term risk of type 2 diabetes, cardiovascular events, and sleep apnea, making it a superior value for money in the Canadian healthcare system.

Intermittent energy restriction (IER) using moderate energy restriction interspersed with diet breaks achieves equivalent fat loss and fat-free mass retention compared to continuous energy restriction (CER) in resistance-trained adults, while significantly reducing hunger and desire to eat.

If you are resistance-trained and want to lose fat, using an intermittent dieting strategy (e.g., 3 weeks of moderate restriction followed by 1 week of maintenance calories) is just as effective for preserving muscle and losing fat as continuous dieting. The key advantage is that this approach significantly reduces hunger and desire to eat, making the diet easier to follow psychologically. Ensure you consume 2.3g of protein per kg of body weight daily and maintain your resistance training routine.

Combination therapy of semaglutide (2.4 mg) and cagrilintide (2.4 mg) (CagriSema) produces weight loss (~15.6%) and HbA1c reduction (~2.2%) comparable to the highest dose of tirzepatide (15 mg) in patients with Type 2 Diabetes.

For patients with Type 2 Diabetes and obesity, a new combination injection (CagriSema) containing semaglutide and cagrilintide (both 2.4 mg weekly) achieves significant weight loss (15.6%) and blood sugar control (HbA1c reduction 2.2%), comparable to the highest dose of tirzepatide. This offers a potent option for those who need both glucose and weight management.

Semaglutide (2.4 mg weekly) and Liraglutide (3 mg daily) are effective pharmacological interventions for obesity-related hypertension, with Semaglutide showing superior weight loss and blood pressure reduction compared to Liraglutide.

If lifestyle changes aren't enough, GLP-1 drugs like Semaglutide (Wegovy) are highly effective. You get a 14.9% weight loss and 6.2 mmHg BP drop on average. It's a once-weekly injection, which is more convenient than daily options.

Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) produce significantly greater weight loss and glycemic control than selective GLP-1 receptor agonists by synergistically targeting both incretin pathways.

If you have T2DM or obesity, dual GLP-1/GIP agonists like tirzepatide are currently the most effective pharmacological option for weight loss and blood sugar control, outperforming older GLP-1 drugs. They are taken as a once-weekly injection. Discuss with your doctor if this advanced therapy is appropriate for your specific health profile.

Post-bariatric pharmacotherapy with GLP-1 receptor agonists (specifically liraglutide) effectively augments weight loss and prevents weight regain in patients who have undergone Roux-en-Y gastric bypass or sleeve gastrectomy.

If you have had bariatric surgery and are regaining weight, talk to your doctor about adding a GLP-1 medication like liraglutide. It is taken as a daily injection, starting at a low dose to minimize side effects like nausea, and can help you lose additional weight or stop regaining it. This is a standard, evidence-based next step when surgery alone is not enough.